Increased medication costs in early-stage CKD (as compared to non-CKD) were largely driven by greater rates of prescriptions for statins, angiotensin converting enzyme inhibitors and other diabetes medications; higher rates of prescriptions for angiotensin receptor blockers and cardiovascular medications drove increased costs as CKD progressed. This evidence concerns the gene ACE and diabetes mellitus.